Phase II Study of Concurrent Continuous Temozolomide (TMZ) and Tamoxifen (TMX) for Recurrent Malignant Astrocytic Gliomas

被引：0
|
作者：
Alexander M. Spence
Richard A. Peterson
Jeffrey D. Scharnhorst
Daniel L. Silbergeld
Robert C. Rostomily
机构：
[1] University of Washington,Department of Neurology, 356465
[2] University of Washington School of Medicine,Departments of Neurology and Neurological Surgery
来源：
Journal of Neuro-Oncology | 2004年 / 70卷
关键词：
anaplastic astrocytoma; glioblastoma multiforme; phase II; Tamoxifen; Temozolomide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose and background: The aim of this study was to assess the frequency of response and toxicity in adults with recurrent anaplastic astrocytoma (AA) or glioblastoma multiforme (GM) treated with concurrent continuous TMZ and TMX.
引用
收藏
页码：91 / 95
页数：4
相关论文
共 50 条
  • [21] Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients
    Silvani, A
    Eoli, M
    Salmaggi, A
    Lamperti, E
    Maccagnano, E
    Broggi, G
    Boiardi, A
    JOURNAL OF NEURO-ONCOLOGY, 2004, 66 (1-2) : 203 - 208
  • [22] Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas
    Grossman, Stuart A.
    Carson, Kathryn A.
    Phuphanich, Surasak
    Batchelor, Tracy
    Peereboom, David
    Nabors, L. Burt
    Lesser, Glenn
    Hausheer, Fredrick
    Supko, Jeffrey G.
    NEURO-ONCOLOGY, 2008, 10 (04) : 608 - 616
  • [23] A phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas
    Odia, Yazmin
    Iwamoto, Fabio M.
    Moustakas, Argirios
    Fraum, Tyler J.
    Salgado, Carlos A.
    Li, Aiguo
    Kreisl, Teri N.
    Sul, Joohee
    Butman, John A.
    Fine, Howard A.
    JOURNAL OF NEURO-ONCOLOGY, 2016, 127 (01) : 127 - 135
  • [24] Phase II Trial of Cisplatin Plus Temozolomide, in Recurrent and Progressive Malignant Glioma Patients
    Antonio Silvani
    Marica Eoli
    Andrea Salmaggi
    Elena Lamperti
    Elio Maccagnano
    Giovanni Broggi
    Amerigo Boiardi
    Journal of Neuro-Oncology, 2004, 66 : 203 - 208
  • [25] A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas
    Jimmy Ruiz
    Doug Case
    Gina Enevold
    Robin Rosdhal
    Stephen B. Tatter
    Thomas L. Ellis
    Richard P. McQuellon
    Kevin P. McMullen
    Volker W. Stieber
    Edward G. Shaw
    Glenn J. Lesser
    Journal of Neuro-Oncology, 2012, 106 : 611 - 617
  • [26] A phase II trial of thalidomide and procarbazine in adult patients with recurrent or progressive malignant gliomas
    Ruiz, Jimmy
    Case, Doug
    Enevold, Gina
    Rosdhal, Robin
    Tatter, Stephen B.
    Ellis, Thomas L.
    McQuellon, Richard P.
    McMullen, Kevin P.
    Stieber, Volker W.
    Shaw, Edward G.
    Lesser, Glenn J.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 106 (03) : 611 - 617
  • [27] A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
    van Meerbeeck, JP
    Baas, P
    Debruyne, C
    Smit, EF
    van Klaveren, RJ
    Galdermans, D
    Lentz, MA
    Manegold, C
    Giaccone, G
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (06) : 779 - 783
  • [28] A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
    Vasilios Karavasilis
    Vassiliki Kotoula
    George Pentheroudakis
    Despina Televantou
    Sofia Lambaki
    Sofia Chrisafi
    Mattheos Bobos
    George Fountzilas
    Journal of Neurology, 2013, 260 : 1469 - 1480
  • [29] Phase II trial of temozolomide and reirradiation using conformal 3D-radiotherapy in recurrent brain gliomas
    Osman, Mohammed A. M.
    ANNALS OF TRANSLATIONAL MEDICINE, 2014, 2 (05)
  • [30] A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma
    Huang, Jiayi
    Chaudhary, Rekha
    Cohen, Adam L.
    Fink, Karen
    Goldlust, Samuel
    Boockvar, John
    Chinnaiyan, Prakash
    Wan, Leping
    Marcus, Stephen
    Campian, Jian L.
    JOURNAL OF NEURO-ONCOLOGY, 2019, 142 (03) : 537 - 544
12345